INM004: Polyclonal Neutralizing Antibodies Against Shiga Toxin as a Treatment for Hemolytic Uremic Syndrome
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI). Shiga toxin (Stx)-producing <i>Escherichia coli</i>-associated HUS (STEC-HUS) is one of the leading causes of AKI in childr...
Saved in:
| Main Authors: | Marta Rivas, Mariana Pichel, Vanesa Zylberman, Mariana Colonna, Marina Valerio, Carolina Massa, Romina Pardo, Andrés E. Ciocchini, Santiago Sanguineti, Ian Roubicek, Linus Spatz, Fernando Alberto Goldbaum |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6651/17/6/282 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Characterization of six Shiga toxin-producing Escherichia coli (STEC) strains carrying Stx2-phages from Colombia
by: Brayan Stiven Arango, et al.
Published: (2022-08-01) -
The frequency of detection of markers of Сytomegalovirus infection in children with recurrent respiratory diseases in patients with Shiga-toxin-associated hemolytic-uremic syndrome (STEC-HUS)
by: I. B. Repina, et al.
Published: (2021-04-01) -
Use of complement C5-inhibitor eculizumab in patients with infection-associated hemolytic uremic syndrome – a case-series report
by: Petra Varga, et al.
Published: (2025-03-01) -
Neurological Manifestations of Hemolytic Uremic Syndrome: A Comprehensive Review
by: Una Tonkovic, et al.
Published: (2025-07-01) -
Eculizumab is efficacious and safe in pediatric patients with various forms of hemolytic uremic syndrome: a retrospective clinical experience of a tertiary center
by: Naama Lax, et al.
Published: (2025-04-01)